<DOC>
	<DOCNO>NCT02429388</DOCNO>
	<brief_summary>Prospective , open-label , randomized cohort study compare add high-dose spironolactone usual heart failure care versus usual care patient acute decompensated heart failure . Patients randomize 1:1 fashion either usual care high-dose spironolactone plus usual care . Both arm study continue treatment ADHF euvolemia define resolution pulmonary edema , peripheral edema , abdominal bloating and/or jugular venous distention . Assessment clinical status serum electrolyte , symptom renal function perform accordance standard care .</brief_summary>
	<brief_title>High-Dose Aldactone Treatment Diuretic Resistant Heart Failure</brief_title>
	<detailed_description>Congestive heart failure ( CHF ) common currently affect estimate 6.6 million adult United States ( 1 ) . In addition highly prevalent , CHF responsible ~ 1 million hospital discharge per year approximately 50 % patient CHF die within 5 year make highly morbid lethal disease ( 1 ) . Manifestations CHF include symptom volume overload dyspnea , abdominal bloating and/or fatigue . The genesis symptom begin loss integrity arterial circulation due decrease cardiac output ( 2 ) . Decreased activation mechanoreceptors carotid sinus , leave ventricle , aortic arch renal afferent arteriole due low systemic arterial pressure stimulate sympathetic nervous system ( SNS ) , renal-angiotensin-aldosterone system ( RAAS ) non-osmotic release arginine vasopressin ( 3 ) . As result , sodium reabsorption proximal tubule follow water absorption increase cause accumulation intravascular volume compensate arterial underfilling ( 4 ) . Consequently , activation neurohumoral reflex result increased cardiac afterload preload , cardiac remodeling , hyponatremia pulmonary edema ( 5 ) . Renal vasoconstriction , sodium water retention lead continuous positive feedback loop salt water accumulation accompany renal vasoconstriction ( 6 ) . Diuretic therapy common mean relieve congestion acute decompensated heart failure ( ADHF ) approximately 90 % patient treat loop diuretic ( 7 ) . Although loop diuretic cornerstone ADHF care carry high level recommendation American Heart Association ( Class I ) ; guideline support low level evidence ( Class C ) ( 8 ) . While effective natriuresis , loop diuretic know stimulate SNS RAAS , adverse consequence heart failure ( 9,10 ) . Not RAAS system stimulate due change arterial filling , furosemide block sodium chloride transport macula densa cause renin release independent renal sodium loss ( 11 ) . With increase stimulation renin release , vasoconstriction renal artery ensues cause exacerbate renal insufficiency ( 12 ) . Long-term utilization loop diuretic result hypertrophy distal nephron increase expression sodium chloride co-transporter ( 13 ) . These change along increase aldosterone level enhance distal sodium reabsorption prevent aldosterone escape ( 14 ) . In treat heart failure patient population , diuretic resistance encounter commonly escalate dos furosemide may utilize achieve fluid loss ( 15 ) . Clinically , use high-doses loop diuretic associate great rate clinical event mechanical ventilation myocardial infarction compare low-dose loop diuretic ( 16 ) . High-dose loop diuretic administration associate worsen renal function ( 17 ) , increase length hospital stay great in-hospital mortality ( 17-19 ) . There fact linear correlation diuretic dose mortality ( 20 ) . Given potential hazard administer loop diuretic CHF patient , remain option limit . Changing diuretic strategy bolus continuous loop diuretic infusion appear change overall outcome ( 21 ) . Alternative strategy relieve congestion include inhibition distal nephron use thiazide diuretic . Thiazide diuretic work synergistically loop diuretic induce natriuresis independent association worsen renal function death ( 20,22 ) . Utilizing inotropes increase renal perfusion pressure may improve natriuresis , however , come price increase mortality regardless whether beta-adrenergic agonist ( dobutamine ) phosphodiesterase inhibitor use ( 23,24 ) . Ultrafiltration mechanical unload heart another therapeutic option , however find ineffective associate worsen renal function ( 25 ) . Even low dos dopamine nesiritide effective improve outcomes patient cardiorenal syndrome ( 26 ) . Higher dose spironolactone recently show safe prospective cohort treat acute decompensated heart failure ( 27 ) . Recently case report publish show patient hospitalized congestive heart failure , worsen renal function diuretic resistance able diuresed without adverse effect renal function hyperkalemia treat escalate dos spironolactone ( 28 ) The study prospective , open-label , randomized cohort study compare add high-dose spironolactone usual heart failure care versus usual care patient acute decompensated heart failure . Patients randomize 1:1 fashion either usual care high-dose spironolactone plus usual care . Both arm study continue treatment ADHF euvolemia define resolution pulmonary edema , peripheral edema , abdominal bloating and/or jugular venous distention . Assessment clinical status , urine serum electrolyte , symptom renal function perform accordance standard care .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Sodium Potassium Chloride Symporter Inhibitors</mesh_term>
	<mesh_term>Diuretics , Potassium Sparing</mesh_term>
	<mesh_term>Sodium Channel Blockers</mesh_term>
	<criteria>1 . 18 year old patient congestive heart failure 2 . Hypervolemic least 2 follow criterion : 1 ) Peripheral edema ; 2 ) jugular venous distention great 7 cm ; 3 ) radiographic pulmonary edema pleural effusion ; 4 ) enlarge liver ascites ; 5 ) pulmonary rale , paroxysmal nocturnal dyspnea orthopnea 3 . Diuretic resistance define loop diuretic requirement furosemide great equal 160 mg IV total daily dose equivalent dose torsemide bumetanide . ( 1 mg bumetanide = 10 mg torsemide = 20 mg furosemide ) 4 . Estimated glomerular filtration rate ( eGFR ) &gt; 30ml/min . accord MDRD Study equation time admission . 5 . Female patient child bear potential must negative urine pregnancy test eligible . 1 . Acute coronary syndrome 2 . Patients baseline eGFR &lt; 30 ml/min accord MDRD equation . 3 . Baseline potassium serum concentration 5.3 meq/L 4 . Requirement intravenous pressor 5 . Systemic infection 6 . Patients concomitant endstage liver disease 7 . Significant valvular disease 8 . Patients pulmonary embolism 9 . Patients high output heart failure 10 . Pregnant patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Spironolactone</keyword>
	<keyword>Diuretics</keyword>
</DOC>